{
  "id": 264655,
  "title": "Psilocybin therapy sessions for PTSD are mostly silent, study finds",
  "url": "https://urgent.news/2026/08/07/psilocybin-therapy-sessions-for-ptsd-are-mostly-silent-study-finds",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T12:00:56.000Z",
  "source": {
    "name": "PsyPost",
    "slug": "psypost",
    "url": "https://www.psypost.org/psilocybin-therapy-sessions-for-ptsd-are-mostly-silent-study-finds/"
  },
  "original_language": "en",
  "account": "A study published in the Journal of Psychopharmacology reveals that during high-dose psilocybin sessions for PTSD, participants and support staff mostly remain silent. Psilocybin, a compound in \"magic\" mushrooms, is being researched as a treatment for mental health issues like PTSD, which stems from traumatic events. Clinical trials typically involve controlled administration by trained staff, but there's a misconception that patients receive talk therapy while under the drug's influence. Guy M. Goodwin, from Compass Pathways, clarifies that the treatment is more about the drug's effect than traditional psychotherapy. The research team examined data from a trial with 22 adults diagnosed with PTSD. After receiving a 25mg dose of COMP360 psilocybin, participants mostly stayed silent, with silence making up 78% of the time during the administration phase. This silent approach contrasts with preparation and follow-up sessions, where speaking occurred more frequently. Participants and staff reported that the quiet method was effective and impactful.",
  "summary": "A recent study in the Journal of Psychopharmacology reveals that during high-dose psilocybin treatment sessions for PTSD, participants and support staff spend most of their time in silence. Psilocybin, a psychoactive compound found in \"magic\" mushrooms, has been explored as a potential treatment for mental health conditions like PTSD. Typically administered in a controlled setting with trained support staff, the treatment relies on quiet, unobtrusive presence rather than active talk therapy. The researchers analyzed data from a clinical trial involving 22 adult participants with PTSD and moderate to severe symptoms. After receiving a single 25-milligram dose of COMP360 psilocybin, most participants experienced a clinically significant reduction in symptoms and found the treatment preferable to previous therapies. The immediate impact of the treatment stood out to the researchers, challenging the misconception that patients undergo traditional talk therapy while under the drug's influence.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}